Search results
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating...
Benzinga· 2 days agoOSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant At the American Transplant Congress 2024 (June 1-5 Philadelphia) Nantes,
ASCO24: Akeso’s bispecific vvonescimab faces a rocky road ahead in NSCLC
Pharmaceutical Technology via Yahoo Finance· 6 days agoEven so, the possible FDA approval of ivonescimab would serve as a testimony to Akeso’s in-house...
Exploring Three Growth Companies With High Insider Ownership On Euronext Paris
Simply Wall St. via Yahoo Finance· 7 days agoAs global markets navigate through varying performances, with the pan-European STOXX Europe 600...
More Salty Diets Linked to Higher Risk of Atopic Dermatitis
MedPage Today· 2 days agoA higher level of daily sodium intake was associated with an increased risk of atopic dermatitis, a...
'Practice Changing' Trial for Inoperable Locally Advanced NSCLC
MedPage Today· 5 days agoEGFR testing now needed for all patients with stage III disease, experts say
ASCO: Cautious Big Pharmas double down on past wins—steering clear of radioligands and cell therapy
FierceBiotech· 2 days agoThis year’s American Society of Clinical Oncology (ASCO) conference in Chicago marked a return to...